D
Dimitri N.M. Papatsonis
Researcher at University Medical Center Utrecht
Publications - 96
Citations - 2884
Dimitri N.M. Papatsonis is an academic researcher from University Medical Center Utrecht. The author has contributed to research in topics: Pregnancy & Randomized controlled trial. The author has an hindex of 24, co-authored 90 publications receiving 2558 citations. Previous affiliations of Dimitri N.M. Papatsonis include Royal Women's Hospital.
Papers
More filters
Reference EntryDOI
Calcium channel blockers for inhibiting preterm labour.
TL;DR: Calcium channel blockers reduced the number of women giving birth within seven days of receiving treatment and reduced the requirement for women to have treatment ceased for adverse drug reaction when compared with any other tocolytic agent.
Journal ArticleDOI
Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): A multicentre, open-label randomised controlled trial
Sophie Liem,Ewoud Schuit,Maud A. Hegeman,Joke M.J. Bais,Karin de Boer,Kitty W.M. Bloemenkamp,Jozien T. J. Brons,Hans Duvekot,Bas Nij Bijvank,Maureen T.M. Franssen,Ingrid Gaugler,Irene M. de Graaf,Martijn A. Oudijk,Dimitri N.M. Papatsonis,Paula J.M. Pernet,Martina Porath,Liesbeth Scheepers,Marko Sikkema,Jan Sporken,Harry Visser,Wim van Wijngaarden,Mallory Woiski,Mariëlle G. van Pampus,Ben W.J. Mol,Dick J. Bekedam +24 more
TL;DR: In unselected women with a multiple pregnancy, prophylactic use of a cervical pessary does not reduce poor perinatal outcome.
Reference EntryDOI
Oxytocin receptor antagonists for inhibiting preterm labour
TL;DR: This review failed to demonstrate the superiority of atosiban over betamimetics or placebo in terms of tocolytic efficacy or infant outcomes, and suggests that calcium channel blockers (mainly nifedipine) are associated with better neonatal outcome and fewer maternal side-effects than betamicetics.
Journal ArticleDOI
Calcium channel blockers for inhibiting preterm labour and birth
Vicki Flenady,Aleena M. Wojcieszek,Dimitri N.M. Papatsonis,Owen Stock,Linda Murray,Luke A Jardine,Bruno Carbonne +6 more
TL;DR: Comparing CCBs (mainly nifedipine) with other tocolytics by type (including betamimetics, glyceryl trinitrate (GTN) patch, non-steriodal anti inflammatories (NSAID), magnesium sulphate and ORAs), no significant reductions were shown in primary outcome measures of birth within 48 hours of treatment or perinatal mortality.
Journal ArticleDOI
Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): An open-label, randomised controlled trial
Kim Broekhuijsen,Gert Jan Van Baaren,Maria G. van Pampus,Wessel Ganzevoort,J. Marko Sikkema,Mallory Woiski,Martijn A. Oudijk,Kitty W.M. Bloemenkamp,Hubertina C.J. Scheepers,Henk A. Bremer,Robbert J.P. Rijnders,Aren J. van Loon,Denise A. M. Perquin,Jan Sporken,Dimitri N.M. Papatsonis,Marloes E. van Huizen,Corla B. Vredevoogd,J.T.J. Brons,M. Kaplan,Anton H. van Kaam,Henk Groen,Martina Porath,Paul P. van den Berg,Ben W.J. Mol,Maureen T.M. Franssen,Josje Langenveld +25 more
TL;DR: For women with non-severe hypertensive disorders at 34-37 weeks of gestation, immediate delivery might reduce the already small risk of adverse maternal outcomes, however, it significantly increases the risk of neonatal respiratory distress syndrome, therefore, routine immediate delivery does not seem justified and a strategy of expectant monitoring until the clinical situation deteriorates can be considered.